Head of Chemistry at CRUK Manchester Institute.
I am the Head of Chemistry at Cancer Research UK’s Drug Discovery Unit in Manchester. The team here recently developed and characterised a novel inhibitor of poly(ADP-ribose) glycohydrolase (PARG), an enzyme that performs a critical role in the repair of DNA single strand breaks. In our 2016 publication we demonstrated that, whilst inhibiting subsequent steps on the same repair pathway, the PARG inhibitor’s pharmacology differs from that of the more thoroughly studied PARP inhibitor olaparib. When considering how to facilitate access to this novel tool compound, we learnt of "Ximbio", Cancer Research Technology’s research tool platform. Through pre-publication access, Ximbio were able to support the synthesis of a batch of this compound in order to make it available to academic, commercial and research tool reseller customers, immediately after its first public disclosure at the 2016 American Association for Cancer Research (AACR) meeting in New Orleans.
Dr. Allan Jordan, Cancer Research UK Manchester Institute